68682-48-4

Usage

Uses

Used in Fragrance and Flavor Industry:
Methyl 2-methyl-2-(4-methylphenyl)propanoate is used as a fragrance and flavoring agent due to its pleasant odor and fruity, floral scent. It is commonly found in perfumes, colognes, and other scented products.
Used as a Solvent:
Methyl 2-methyl-2-(4-methylphenyl)propanoate is also utilized as a solvent in various applications.
Used as an Intermediate in Organic Synthesis:
Methyl 2-methyl-2-(4-methylphenyl)propanoate serves as an intermediate in the synthesis of other organic compounds, including pharmaceuticals and agrochemicals.

Upstream product

• 547-63-7 Methyl isobutyrate 
• 106-38-7 para-bromotoluene 
• 20430-18-6 2-methyl-2-(p-tolyl)propanoic acid 
• 74-88-4 methyl iodide 
• 106-43-4 para-chlorotoluene 
• 79443-97-3 methyl 2-(4-methylphenyl)propanoate 
• 938-94-3 (R,S)-2-(4'-methylphenyl) propionic acid 
• 23786-13-2 methyl p-tolylacetate 

Downstream Products

• 147247-29-8 methyl 2-(4-(bromomethyl)phenyl)-2-methylpropanoate 
• 1606974-89-3 2-(4-((2-(3-chlorophenyl)-6-ethylpyrimidin-4-yl)methyl)phenyl)-2-methylpropan-1-ol 
• 1606974-88-2 2-(4-((2-(3-chlorophenyl)-6-ethylpyrimidin-4-yl)methyl)phenyl)-2-methylpropanamide 
• 1606977-29-0 2-(4-((2-(3-chlorophenyl)-6-ethylpyrimidin-4-yl)methyl)phenyl)-2-methylpropanoic acid 
• 1606977-28-9 methyl 2-(4-((2-(3-chlorophenyl)-6-ethylpyrimidin-4-yl)methyl)phenyl)-2-methylpropanoate 
• 879484-59-0 methyl 2-methyl-2-{4-[(4-methyl-1-piperazinyl)methyl]phenyl}propanoate 
• 1247008-25-8 [1-[[4-[1,1-dimethyl-2-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]-2-oxoethyl]phenyl]methyl]-4-piperidinyl]methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate 
• 1247008-27-0 [1-[[4-[1,1-dimethyl-2-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]-2-oxoethyl]phenyl]methyl]-4-piperidinyl]methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate hydrochloride 
• 1247008-23-6 2-[4-[[4-(3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyloxymethyl)-1-piperidinyl]methyl]phenyl]-2-methylpropanoic acid 
• 1247008-47-4 [1-[[4-(2-methoxy-1,1-dimethyl-2-oxoethyl)phenyl]methyl]-4-piperidinyl]methyl 3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxylate 

Relevant academic research and scientific papers

Br?nsted Acid-Catalyzed Intramolecular Hydroarylation of β-Benzylstyrenes

Using triphenylmethylium tetrakis(pentafluorophenyl)borate as a convenient Br?nsted acid precatalyst, β-(α,α-dimethylbenzyl)styrenes are shown to cyclize efficiently to afford a variety of new indanes that possess a benzylic quaternary center. The geminal dimethyl-containing quaternary center is proposed to be necessary to arm the substrate for cyclization through steric biasing.

HETEROARYL INHIBITORS OF PDE4

The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.

Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist

5-HT4 receptor antagonists have been suggested to have clinical potential in treatment of atrial fibrillation, diarrhea-prone irritable bowel syndrome and urinary incontinence. Recently, the use of 5-HT4 antagonists has been suggeste

Falcipain inhibitors: Optimization studies of the 2-pyrimidinecarbonitrile lead series

Falcipain-2 and falcipain-3 are papain-family cysteine proteases of the malaria parasite Plasmodium falciparum that are responsible for host hemoglobin hydrolysis to provide amino acids for parasite protein synthesis. Different heteroarylnitrile derivatives were studied as potential falcipain inhibitors and therefore potential antiparasitic lead compounds, with the 5-substituted-2- cyanopyrimidine chemical class emerging as the most potent and promising lead series. Through a sequential lead optimization process considering the different positions present in the initial scaffold, nanomolar and subnanomolar inhibitors at falcipains 2 and 3 were identified, with activity against cultured parasites in the micromolar range. Introduction of protonable amines within lead molecules led to marked improvements of up to 1000 times in activity against cultured parasites without noteworthy alterations in other SAR tendencies. Optimized compounds presented enzymatic activities in the picomolar to low nanomolar range and antiparasitic activities in the low nanomolar range.

Palladium-catalyzed-arylattion of esters With chloroarenes

Palladium-catalyzed α-arylations of esters with chloroarenes are reported. The reactions of chloroarenes with the sodium enolates of tert-butyl propionate and methyl isobutyrate occur in high yields with 0.2-1 mol % of {[P(f-Bu)3]PdBr}2/s

FXR AGONISTS

Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.

2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS

Substituted heteroaryl nitrile derivatives of Formula (I) processes for their preparation, pharmaceutical compositions comprising such compounds and use of the compounds as cysteine protease inhibitors are provided.

NOVEL ADENINE COMPOUND AND USE THEREOF

A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene; etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents -COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

Piperazine compounds and medicinal use thereof

The present invention relates to a piperazine compound of the formula wherein R1and R2are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4and R5are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6and R7are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8and R9are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.